DGAP-News: PAION AG / Key word(s): Research Update
INVITATION TO CONFERENCE CALL OF PAION ABOUT THE PROJECT STATUS OF
REMIMAZOLAM IN JAPAN
14.10.2014 / 07:30
---------------------------------------------------------------------
INVITATION TO CONFERENCE CALL OF PAION ABOUT THE PROJECT STATUS OF
REMIMAZOLAM IN JAPAN
- Explanations to the ad hoc release published on 10 October 2014
- Conference Call today at 4 p.m. CEST (3 p.m. BST, 10 a.m. EDT)
Aachen, 14 October 2014 - PAION AG, a Specialty Pharma Company (ISIN
DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) will host an
explanatory public conference call today at 4 p.m. CEST (3 p.m. BST, 10
a.m. EDT) in connection with the ad-hoc release published on Friday 10
October 2014 about the project status of Remimazolam in Japan. PAION will
explain the current state of discussion with the Japanese partner ONO
Pharmaceutical. The conference call will initially start in English
language and continues at 4.45 p.m. in German language.
To access the English call starting at 4 p.m., participants may dial from
- Germany +49 (0) 69 7104 45598,
- UK +44 (0) 20 3003 2666 and
- US +1 212 999 6659
- (other countries: please use the UK number).
When prompted, you will be asked to give the password "PAION English". The
conference call will be supplemented by a webcast presentation which can be
accessed during the call under the following link:
www.meetingzone.com/presenter?partCEC=4456014
To access the German call starting at 4.45 p.m., participants may dial from
- Germany +49 (0) 69 7104 45598,
- UK +44 (0) 20 3003 2666 and
- US +1 212 999 6659
- (other countries: please use the UK number).
When prompted, you will be asked to give the password "PAION German". The
conference call will be supplemented by a webcast presentation which can be
accessed during the call under the following link:
www.meetingzone.com/presenter?partCEC=7394887
###
About Remimazolam
Remimazolam is an innovative short-acting general anaesthetic/sedative. Due
to its short duration of action and good controllability, it has a
preferable efficacy and safety profile relative to other currently marketed
anaesthesia compounds. The rapid offset of Remimazolam's effect is due to
its metabolism by tissue esterase enzymes that are widely distributed
throughout the body. Remimazolam has potential in three indications:
- Procedural sedation
- General anaesthesia
- ICU sedation
Remimazolam is available for licensing outside Japan, China, Russia (CIS)
Turkey, MENA Region, South Korea and Canada, where the compound is
partnered with, Ono Pharmaceutical, Yichang Humanwell, R-Pharm, TR-Pharm,
Hana Pharm and Pendopharm.
About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in
Aachen, Germany with a second site in Cambridge, UK. The company has a
track record in developing hospital-based treatments for which there is
substantial unmet medical need. PAION's strategy is to extend its business
model from a pure development company to a specialty pharmaceutical company
with a focus on anaesthesia products. Remimazolam is intended to be the
basis for its future marketing activities.
PAION Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com
Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.
---------------------------------------------------------------------
14.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
291414 14.10.2014
DGAP-News: INVITATION TO CONFERENCE CALL OF PAION ABOUT THE PROJECT STATUS OF REMIMAZOLAM IN JAPAN
| Source: EQS Group AG